학술논문
Clinical Efficacy and Adverse Event of Remdesivir Treatment in Seven COVID-19 Cases with Respiratory Failure / レムデシビルで治療された呼吸不全合併COVID-19 7 例において観察された臨床的効果と有害事象について
Document Type
Journal Article
Author
Chihiro TAKAI; Daisuke ARAI; Genta NAGAO; Hidenori TAKAHASHI; Ichiro NAKACHI; Kayo MISUMI; Kensuke FUJITA; Masayoshi KOMURA; Rie BABA; Ryo FUJII; Shigenobu KAMIMOTO; Shunichiro KONISHI; Sou YAMADA; Takahiro YAMANAKA; Takaomi KOBAYASHI; Takashi KADOYA; Takayuki OGURA; Takuya KIMURA; Taro OKABE; Tetsuro KAMO; Toshiki KOINUMA; Yoshihiro HAGIWARA; Yusuke MINAGAWA; 三角 香世; 仲地 一郎; 加茂 徹郎; 小倉 崇以; 小村 賢祥; 小林 孝臣; 小西 駿一郎; 山中 隆広; 山田 宗; 岡部 太郎; 木村 拓哉; 皆川 裕祐; 神元 繁信; 荒井 大輔; 萩原 祥弘; 藤井 遼; 藤田 健亮; 角谷 隆史; 長尾 元太; 馬場 里英; 高井 千尋; 髙橋 秀徳; 鯉沼 俊貴
Source
感染症学雑誌 / Kansenshogaku Zasshi. 2021, 95(2):147
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
A preliminary report from a global study showed that remdesivir, a nucleoside analog pro-drug that was originally developed as a therapeutic drug against Ebola virus, may exert clinical efficacy in cases of COVID-19, by shortening the time to recovery. We had the opportunity to use this new drug in the treatment of 7 COVID-19 patients with respiratory failure.